FDA Opens Public Comment Period on Generative AI Medical Device Framework
The U.S. Food and Drug Administration (FDA) has taken a significant step toward formalizing oversight of generative AI (GenAI) in medical devices by publishing a draft framework and opening a public comment period.
The framework addresses a growing category of software-based medical tools that use generative AI to perform tasks such as clinical documentation, diagnostic image interpretation, and patient decision support. Unlike traditional medical devices with fixed algorithms, GenAI-enabled devices can produce variable outputs based on training data, raising new questions about predictability, safety, and reproducibility.
Key areas the FDA is exploring include:
- Risk classification: How to categorize GenAI medical devices based on potential harm if the software malfunctions or produces incorrect outputs.
- Transparency requirements: What disclosures manufacturers must provide about how GenAI models are trained, validated, and updated.
- Post-market surveillance: How the agency will monitor AI devices that continue learning or being updated after deployment.
- Validation standards: Expectations for demonstrating that a generative AI model's outputs are reliable and safe for specific clinical use cases.
The comment period allows healthcare providers, industry stakeholders, researchers, and patient advocates to weigh in before the FDA finalizes its approach. The agency has historically taken an iterative stance toward AI regulation, releasing multiple guidance documents over the past several years rather than a single sweeping rule.
Experts note that GenAI introduces distinct regulatory challenges compared to earlier generations of AI in healthcare. Traditional AI/ML-based software often relies on locked algorithms, whereas generative models may adapt or produce novel content, making consistent performance verification more complex.
The FDA's move aligns with broader regulatory efforts internationally, as agencies in the European Union, United Kingdom, and other regions are similarly developing frameworks for AI in medical contexts.